Yang JC, Han B, De La Mora Jimenez E, Lee JS, et al. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncol 2023 Dec 28:S1556-0864(23)02432.
PMID: 38159809